Asset profile
iPSC-CL
Cell therapy
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 8 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 64 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| iPSC-CL: this drug | Phase 1 | Cell therapy | Cardiac cell therapy | ||
| CardiAMP | Phase 3 | Cell therapy | Cardiac cell therapy | ||
| Deramiocel (CAP-1002) | Phase 3 | Cell therapy | Cardiac cell therapy | ||
| HiCM-188 (allogeneic iPSC-Cardiomyocytes) | Phase 3 | Cell therapy | Cardiac cell therapy | ||
| ADR-002K | Phase 2 | Cell therapy | Cardiac cell therapy | ||
| HS-001 | Phase 1/2 | Cell therapy | Cardiac cell therapy | ||
| HucMSC Intramyocardial Therapy | Phase 1/2 | Cell therapy | Cardiac cell therapy | ||
| Anhui HygeianCells EE001 | Phase 1 | Biologic (subtype unspecified) | Cardiac cell therapy | ||
| STM01 | Phase 1 | Cell therapy | Cardiac cell therapy | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | ||
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 |
…and 53 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
September 2027 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.